A photo of Carolyn Lutzko.

Director, Cell Manipulation Laboratory and Translational Development, Translational Core Laboratory

Division Director, Regenerative Medicine and Cellular Therapies, Hoxworth Blood Center

Associate Professor, UC Department of Pediatrics

513-803-2420

513-636-1446

Biography & Affiliation

Research Interests

Regulating human pluripotent stem cell; somatic cell reprogramming in iPSC; human embryonic stem cell physiology and differentiation; hESC; cystic fibrosis

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Research Divisions

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases



Blog Posts

Highlighting Heroes: Turnaround Enables COVID-19 Testing for Employees and Patients

Infectious Diseases and Vaccines

Highlighting Heroes: Turnaround Enables COVID-19 Testing for Employees and Patients

Carolyn M. Lutzko, PhD4/2/2020

Education

BA: University of Guelph, S.Sc. Hon, Molecular Biology and Genetics Guelph, Ontario, Canada 1992.

PhD: University of Toronto, PhD Department of Laboratory Medicine Toronto, Ontario, Canada 1999.

Fellowship: Childrens Hospital Los Angeles Department of Pediatrics Division of Research Immunology/BMT Los Angeles, CA, 1999-2002.

Publications

Selected Publication

Integrated Genomic Analysis of Diverse Induced Pluripotent Stem Cells from the Progenitor Cell Biology Consortium. Salomonis, N; Dexheimer, PJ; Omberg, L; Schroll, R; Bush, S; Huo, J; Schriml, L; Sui, SH; Keddache, M; Mayhew, C; et al. Stem Cell Reports. 2016; 7:110-125.

Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. Nayak, RC; Trump, LR; Aronow, BJ; Myers, K; Mehta, P; Kalfa, T; Wellendorf, AM; Valencia, CA; Paddison, PJ; Horwitz, MS; et al. Journal of Clinical Investigation. 2015; 125:3103-3116.

Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. Rubinstein, JD; Zhu, X; Lutzko, C; Leemhuis, T; Cancelas, JA; Jodele, S; Bollard, CM; Hanley, PJ; Davies, SM; Grimley, MS; et al. Blood Advances. 2020; 4:3252-3257.

Mouse models of neutropenia reveal progenitor-stage-specific defects. Muench, DE; Olsson, A; Ferchen, K; Pham, G; Serafin, RA; Chutipongtanate, S; Dwivedi, P; Song, B; Hay, S; Chetal, K; et al. Nature. 2020; 582:109-114.

EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects. Rubinstein, JD; Burns, K; Absalon, M; Lutzko, C; Leemhuis, T; Chandra, S; Hanley, PJ; Keller, MD; Davies, SM; Nelson, A; et al. Pediatric Blood and Cancer. 2020; 67.

CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. Khandelwal, P; Chaturvedi, V; Owsley, E; Lane, A; Heyenbruch, D; Lutzko, CM; Leemhuis, T; Grimley, MS; Nelson, AS; Davies, SM; et al. Biology of Blood and Marrow Transplantation. 2020; 26:1-6.

Neutrophils Derived from Genetically Modified Human Induced Pluripotent Stem Cells Circulate and Phagocytose Bacteria In Vivo. Trump, LR; Nayak, RC; Singh, AK; Emberesh, S; Wellendorf, AM; Lutzko, CM; Cancelas, JA. Stem Cells Translational Medicine. 2019; 8:557-567.

Molecular, phenotypic, and sample-associated data to describe pluripotent stem cell lines and derivatives. Daily, K; Sui, SJ H; Schriml, LM; Dexheimer, PJ; Salomonis, N; Schroll, R; Bush, S; Keddache, M; Mayhew, C; Lotia, S; et al. Scientific Data. 2017; 4.

Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency. Nasimuzzaman, M; Lynn, D; Ernst, R; Beuerlein, M; Smith, RH; Shrestha, A; Cross, S; Link, K; Lutzko, C; Nordling, D; et al. Molecular Therapy-Methods & Clinical Development. 2016; 3:16004-16004.